| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8458628 | Radiotherapy and Oncology | 2018 | 8 Pages |
Abstract
An increase in trend for the use of immunotherapy was noted, however, an overwhelming majority of the patients with this disease are still treated without immunotherapy. Addition of immunotherapy to RT is associated with improved OS in MBM. Given the selection biases that are inherent in this analysis, prospective trials investigating the combination of RT, especially SRS and immunotherapy are warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Prashant Gabani, Benjamin W. Fischer-Valuck, Tanner M. Johanns, Leonel F. Hernandez-Aya, Jesse W. Keller, Keith M. Rich, Albert H. Kim, Gavin P. Dunn, Clifford G. Robinson, Michael R. Chicoine, Jiayi Huang, Christopher D. Abraham,